---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030873"
form_type: "8-K"
ticker: "NRXS"
cik: "0001933567"
company_name: "Neuraxis, INC"
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:33:18.351923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives

## Summary
- Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.
- Net loss $2.9M, up 30.5% YoY; operating loss $2.2M, up 97.5%.
- Covered lives grew to 22.5M from 4.5M a year ago; commitment from payer with 12M lives starting Oct 1.
- Submitted RED device to FDA for clearance expected Q4 2024; submitted label expansion to ages 8-21.
- Secured additional $3.0M funding in May; total committed financing $9.1M; cash $1.8M, short-term debt $4.8M.

## SEC filing metadata
- accession: 0001493152-24-030873
- form_type: 8-K
- ticker: NRXS
- cik: 0001933567
- company_name: Neuraxis, INC
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/0001493152-24-030873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030873
- JSON: https://secwatch.observer/filing/0001493152-24-030873.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.